The primary reason I have left this one alone despite monitoring it, is the lack of uptick in their EPI offering. Was looking to see if the market would adopt a cheaper alternative to the expensive one that dominated the market. So far, hasn't happened.
And on Zimhi, I suspect the same thing is going to happen. What we use (Narcan) works, is effective. And having been in the bio investing world for some time, its not surprising to see that the 'established' maintains ts position as long as its 'working'. And the new product is going to likely have a heck of a time gaining market share unless it can demonstrate whats 'out there' already is 'ineffective' in comparison.
So yeah, not expecting zhimhi to gain market share any time soon, cause folks get comfortable with something that works, and they are reluctant to change'..
disclaimer: ADMP is a case study in product approval, but that the market isn't interested in (so far) And the share price reflects it. (but that I monitor cause at this price, if something starts to change?? Could be a nice entry price)
News 
Market Data 
Discover 
